GILEAD'S TWICE-YEARLY SHOT TO PREVENT HIV SUCCEEDS IN LATE-STAGE TRIAL

Summary from the TLDR newsletter

Gilead's lenacapavir was 100% effective in preventing HIV in roughly 2,000 women in a late-stage trial. The results will need to be replicated before Gilead can seek approval from the Food and Drug Administration. Lenacapavir could be on the market as soon as late 2025 if trial results continue to be positive.